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 high-tech technology for highly sensitive test systems is proposed based on conjugates "polymer 
microsphere-bioligand" for express diagnosis of autoantibodies to the modified protein (proteopathy) for 
example, thyroglobulin, using the method of latex agglutination reaction (in vitro). 
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Introduction 
In laboratory practice for immunochemical 
analysis is often used the reaction of latex agglu-
tination (RLA), using diagnostic test systems deri-
ved from polymeric microspheres and specific 
bioligands [1–4]. 
RLA is different from traditional testing me-
thods (double radial immunodiffusion [5] and im-
munoelectrophoresis [6], radioimmunoassay (RIA) 
[7], enzyme-linked immunosorbent assay (ELISA) 
[8], immunochromatographic assay (IHA) [9]) in 
its simplicity, it requires no special equipment and 
allows to carry out a visual record of results in a 
short time. The relative cheapness of analysis, high 
sensitivity, specificity, and reproducibility of the 
RLA method, simplicity and the ability to test 
performance in almost any conditions allow for 
express diagnosis of diseases, both in single and in 
screening studies. 
Test systems for RLA are polymeric micro-
spheres containing on its surface specific bioli-
gands capable to affinity binding with a detectable 
component, thus forming a spatial grid agglo-
merates, which are easily visualized. 
The proposed methodology for the diagnostic test 
systems based on conjugates "polymer microsphere-bio-
ligand" for express diagnosis of autoanti-bodies to 
the modified protein (proteopathy), the example of 
thyroglobulin, is described in detail in the Report 1. 
The purpose of the work was to develop high-
tech technology for highly sensitive test systems 
based on conjugates "polymer microsphere-bio-
ligand" for express laboratory diagnosis of auto-
antibodies to thyroglobulin thyroid underlying 




Styrene, purified from the stabilizer with 5% 
aqueous sodium hydroxide solution, washed with 
water until neutral, dried over calcined calcium 
chloride and twice distilled in a vacuum. Used the 
fraction boiling at 41°C (2.1 kPa), d420 = 0.906 g/cm3. 
Mass fraction is of 99% of the main substance. 
Sodium styrene sulfonate, мass fraction is of 
99% of the main substance. 
Acrolein, a technical product of «Fluka», three 
times distilled at atmospheric pressure. Used the 
fraction boiling at 52°C, d420 = 0.806 g/cm3. 
Azobisisobutyronitrile – initiator, was purified 
by recrystallization from methanol. The melting 
point is 101°C. 
Potassium persulfate – initiator, without further 
purification. Mass fraction is of 99% of the main 
substance. 
Polyvinylpyrrolidone, applied with a molecular 
weight of 40,000, used the mark "reagent grade" 
without further purification. 
(N-Ethyl-N'-(3-dimethylaminopropyl) carbodi-
imide hydrochloride) – «Merck» company.  Purity 
98%. 
Thyroglobulin was obtained at the Mechnikov 
Research Institute of Vaccines and Sera, the 
molecular weight of 600 kDa. Purity is not less 
than 98%. 
Serum samples of patients with diseases of the 
thyroid gland against thyroglobulin (titer immuno-
sorbent assay (ELISA) – 1:3240) were obtained 
from the Diagnostic Center Mechnikov Research 
Institute of Vaccines and Sera. 
Phosphate-buffered saline (pH 7.2), prepared 
by mixing 720 mL of the solution (11.876 g) 
Na2HPO4 in 1000 mL of distilled water and 280 
mL (9.078 g), КH2PO4 in 1000 mL of distilled 
water to the total volume of the solution phosphate 
salts (1000 mL), 9 g NaCl. 
Water – bidistillate. 
 
Methods 
Aggregate stability of polymeric microsphe-
res in a buffer solution (phosphate-buffered 
saline (pH 7.2)) was determined using light and 
A 
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electron microscopes, and deposition in the wells of 
96-well microplates (firms "Lenmed Polimer", 
Russia, "Greiner", Germany). 
Determination of aggregate stability of the 
particles in the wells of 96-well plates was 
performed by the following procedure: 
The first row is contributed to 25 mL of buffer 
solution. Prepared 4% albumin solution in a buffer 
solution and measured it at 25 mL in the first row 
microplates, the concentration of albumin in the 
first hole is equal to 2% of the first series of wells 
in the next two steps (reducing the concentration of 
albumin 2-fold) was performed breeding albumin, 
leaving only the last row with a buffer solution (as 
zero control). 
 
4% → 2 → 1 → 0.5 → 0.25 → 0.125 → 0.06 
→ 0.03 → 0.015 → 0.008 → 0.004 → 0.002% 
 
Next to all the wells of row added to 25 mL 
0.3% strength polymer slurry plate was shaken and 
left at room temperature for 5–6 h. After 6–7 h 
(time of sedimentation of particles of polymer 
slurry) on the bottom of the wells formed 
precipitate point in aggregate stability of particles, 
the particles of aggregate instability agglutinates 
formed in an inverted umbrella. The minimum con-
centration of albumin, in which there is no aggrega-
tion of particles, is determined by the final hole 
with a point precipitate. 
 
To control the specificity of the diagnostic 
test systems a method of inhibition of the re-
action of latex agglutination (RTLA) in 96-well 
microplates is proposed 
 
In a number of 96-well polystyrene microplates 
25 µL saline or buffer solution is inserted. 
In the first well of the row insert 25 µL of 
buffer solution (phosphate-buffered saline pH 7.2) 
containing thyroglobulin with concentration 100 
µg/µL. From the first well in a row dilution is 
carried out of 25 µL buffer containing thyro-
globulin in sub-sequent wells with step 2. 
Introduced into each well of the row human 
serums with high titer in an amount of 25 µL, 
containing not less than 400 IU/µL of autoanti-
bodies to thyroglobulin. 
Keep the system within 3-5 min. 
After 3-5 min in each well introduce 25 mL of 
0.3-0.4% suspension (diagnostic test systems), than 
shake it and leave at room temperature for 5-6 h. 
In the experimental range of diagnostic test 
system agglutination is not taking place or take 
place with increase of serum titer. This indicates 
that the diagnostic test system is specific. 
With a positive reaction (RTLA) at the bottom 
of the microplate a spot precipitate is formed, with 
the negative reaction agglutinate is formed in form 
of inverted "umbrella". 
 
For quantitative control of diagnostic test 
systems a method of reaction of latex agglu-
tination (RLA) in 96-well microplates is 
proposed 
Quantitative detection of autoantibodies to 
thyroglobulin is proposed to be conducted in 96-
well polystyrene plates according to the scheme: 
 
 1 2 3 4 5 6 7 8 9 10 11 12 Dilution 
 NC PC С1 С2 С3 С4 С5 С6 С7 С8 С9 С10 1:10 
 NC-1 PC-1 С1-1          1:20 
 NC-2 PC-2 С1-2          1:40 
 NC-3 PC-3 С1-3          1:80 
 NC-4 PC-4 С1-4          1:160 
 NC-5 PC-5 С1-5          1:320 
 NC-6 PC-6 С1-6          1:640 
 NC-7 PC-7 С1-7          1:1280 
 
1. In well A1 add 50 µL serum with negative 
control (NC).  
2. NC-serum containing no antibody/antigen. 
3. In well A2 add 50 µL of serum with the 
positive control (PC). PC-serum containing anti-
bodies/antigens not less than 100 IU/µL. 
4. To wells A3-A12 introduce 50 µL test sera 
(C1-C10) in a 1:10 dilution. 
5. Into the wells of rows B to H introduce 25 
µL phosphate-buffered saline (0.01 M, pH 7.4). 
6. From the first wells of row A (at 25 µL) in 
the next wells of rows B→C→D→E→F→G→H→ 
(for disposal) in increments of 2 (2-fold dilution) 
perform dilution of solutions. 
7. To each well of the plate introduce 25 µL of 
0.3-0.4% suspension (diagnostic test systems), shake 
the plate and leave at room temperature for 1.5-2 h. 
With positive RLA at the bottom of the wells is 
formed the agglutinates in the form of inverted 
umbrella with a negative – spot precipitate. 
In the analysis of the studied serum their 
maximum dilution giving a positive reaction is 
taken. As a positive reaction in a dilution of studied 
sera understand the value of titers in two or more 
times greater than the value of titers in the negative 
control serum (NC). 
The minimum tested concentration of agglutinate 
determined by the final well with a positive reaction 
(agglutination unit (AU)). The next well, which is not 
observed RLA is called subagglutination unit (SU). 
Вестник МИТХТ, 2013, т. 8, № 5 
79 
 
Synthesis of polymeric suspensions were deter-
mined by the seed polymerization of the monomers 
in the polymer seed particles [10,11], cleaning 
polymer suspensions of residual components of the 
polymerization was performed by microfiltration 
[12], for determination of residual monomer in a 
polymer suspension spectrophotometry was carried 
out [13], determination of particle size and particle 
size distribution were determined by photon – cor-
relation spectroscopy on the device «Malvern» 
(England) [14], the concentration of aldehyde 
groups on the surface of the polymer microspheres 
were determined by conductometric titration [10] 
and the protein concentration was determined by 
the Lowry method [15], detection of autoantibodies 
to thyroglobulin (Tg) immunoassay (ELISA), de-
tection of thyroglobulin (Tg) immunoassay 
(ELISA) [8], covalent binding of the amino groups 
with carboxyl groups bioligands glycine contained 
on the surface polymeric microspheres was per-
formed using the soluble carbodiimides [16]. 
Results and Discussion 
Each of the stages of the technological process: 
the synthesis of polymeric suspensions (TP.1), 
cleaning polymer suspensions of residual compo-
nents of the polymerization (TP.2) isolation and 
purification of specific bioligands (TP.3) bioligands 
specific immobilization on the surface of polymer 
microspheres (TP.4) requires special attention and 
a number of requirements in the development of 
test systems based on conjugates "polymer micro-
sphere-bioligand" for express laboratory diagnosis 
of autoantibodies to thyroglobulin of the thyroid. 
In the first (TP.1) and second (TP.2) stages of 
the process, obtaining polymer suspensions, it was 
necessary to determine the quality criteria of the 
polymer particles and methods of control that 
would meet the requirements for carrier particles 
bioligands (Tg) for the development of diagnostic 
test system for autoantibodies to thyroglobulin. 
Quality criteria of polymer microspheres and 
methods of control are shown in Table 1. 
 
Table 1. Quality criteria of polymeric microspheres, which are used in the development of test systems 
for the detection of autoantibodies to thyroglobulin, and methods of their control 
Indicator Method Display 
The mass fraction of the 
polymer (dry basis),% 
Determination of polymer content 
in the suspension (dry basis), the 
mass fraction of the polymer in % 
For seed polymerization not less than 
0.4, not more than 0.6 
The size of polymer 
microspheres and 
particle size distribution 
Photon-correlation spectroscopy Microsphere diameter 4.0-4.2 microns 
particle size distribution narrow 
(coefficient of variation less than 3%) 
Concentration of 
functional groups 
Conductometric titration The concentration of aldehyde 
groups 1.2–1.4×103 mol/g of 
polymer 
Residual monomer Determination of residual monomer 
in a polymer suspension 
Mass fraction of residual monomer is 
no more than 0.05% 
Aggregate stability Determination of aggregate 
stability of polymeric microspheres 
in a solution of NaCl 
Aggregate stability in the  
0.15–0.25 M solution of NaCl 
 
In the third stage of the process (TP.3) upon receiving a specific bioligand molecule (Tg) were 
determined bioligands quality criteria and methods of control, which are presented in Table 2. 
 
Table 2. Quality criteria of specific bioligands (Tg), which are used in the development of test systems 
to detect autoantibodies to thyroglobulin, and methods of control 
Indicator Method Display 
The degree of purifica-
tion of thyroglobulin 
Electrophoresis in 5% polyacryl-
amide gel 
The degree of purification of 
thyroglobulin at least 98% 
The molecular weight of 
thyroglobulin 
Ultrafiltration using membranes 
«Amicon» Brand X-300 
Dimer with a molecular weight of 
600000 Da 
 
The fourth stage of the process (TP.4) is one of 
the most high-tech processes (method of immobi-
lization on the surface of specific bioligands poly-
mer microspheres). Developed and presented in the 
Report 1 method of immobilization of specific bio-
ligands (Tg) on the surface of polymer micro-
spheres allowed to obtain a highly sensitive test 
system "PM-glycine-TG", which provided a clear 
difference in the test serum samples with high 400–
1700 IU/mL, the average 100–400 IU/mL and a 
low of 20–100 IU/mL content of autoantibodies to 
thyroglobulin (Table 3). 
The results presented in the Report 1 led to the 
establishment of low-waste technology for the test 
of the "PM-glycine-TG" with the use of polymer 
microspheres and thyroglobulin, meeting the requi-
rements of their use in modern clinical and diag-
nostic laboratories in the identification of autoanti-
bodies to thyroglobulin thyroid. 
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Table 3. The results of identification of autoantibodies to thyroglobulin by developed test system in the RLA 
 
Groups surveyed 
Number of sera 
tested 
The range of detection of 
autoantibodies to thyro-
globulin by RLA, IU/mL 
 
Titer RLA 
Healthy donors 30 10–30 1:10–1:40 
Patients with autoimmune 
thyroid disease 
10 30–100 1:40–1:120 
30 100–400 1:120–1:540 
20 400–1000 1:540–1:1620 
10 1000–1700 1:1620–1:3240 
 
Fig. 1 and Fig. 2 shows the process flow and procedural schemes of test systems for the identification 
of autoantibodies to thyroglobulin "PM-glycine-Tg". 
 
 
Fig. 1. Process flow scheme for diagnostic test system "PM-glycine-Tg". 
 
 
Fig. 2. Procedural scheme for diagnostic test-system "PM-glycine-Tg". 
Y1-4 – Pack NaCl, KH2PO4, Na2HPO4, carbodiimide; E-1 – Container of distilled water; E-2 – Tank for preparation of 
phosphate buffer solution (BR); E-31-2 – Tanks with glycine and thyroglobulin; E-41-3 – Preparation tank with glycine BR, 
BR with carbodiimide, BR with thyroglobulin; E-5 – Capacity for purified polymer slurry;  P-6 – Reactor for the immobilization 
process; M-7 –Microfiltration cell; K-8 – Compressor; B-9 – Scales; E-10 – Capacity for the finished product (test systems). 
 
Diagnostic test system "PM-glycine-Tg" is pro-
duced by immobilizing thyroglobulin on the sur-
face of the polymer particles in the interphase layer 
containing glycine. The process is proposed to take 
place in three stages: 
The first stage – getting conjugate "PM-
glycine". 
The reactor (Р-6) from the container (E-5) 
supplied with 0.4% w polymer suspension from the 
tank, to the same from (E-41) 1% glycine buffer 
solution is added and mixing turns on. To maintain 
the required temperature through heat exchange 
jacket reactor (Р-6) water is pumped, the tempe-
rature of which is maintained at +37±0,5°C. 
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Stirring is carried out for 8-10 hours. After 8-10 
hours, the reactor contents (R-6) are fed into the 
microfiltration cell (M-7) equipped with a filter 
membrane with a pore diameter of 0.45 µm. The 
contents of the filter cells (M-7), with stirring 
forced through the membrane, using a compressor 
(K-8). The filtration is carried out until such time as 
the cell will remain the initial volume of the poly-
mer suspension (conjugate "PM-glycine"). After 
that, in the microfiltration cell (M-7) buffer added 
from tank (E-2), and then the filtration, as des-
cribed above, 2 more times. In the process of clean-
ing a concentrate is obtained (buffer particle conju-
gate "PM-glycine"), which is fed to the reactor (P-
6) for the activation of the carboxyl groups of 
glycine contained in the conjugate "PM-glycine". 
Only this method of obtaining particles of con-
jugate "PM-glycine" allow fully locked aldehyde 
groups (1.2×103 mol/g of polymer), contained on 
the surface of 0.4% polymer suspension, by amino 
glycine for 8-10 hours at 37°C. 
The second stage – the activation of the carb-
oxyl groups of glycine contained in the conjugate 
"PM-glycine." 
The second stage of the process is similar to the 
first, except that instead of the concentrate (buffer 
particle conjugate "PM-glycine") contained in the 
reactor (P-6), serves 0.1% buffer carbodiimide, taken 
from the container (E-42), instead of 1% of the glycine 
buffer. Carbodiimide activation process of the carb-
oxyl groups of glycine contained in the conjugate 
"PM-glycine" is carried out for 40-50 minutes. 
The buffer particles of conjugate "PM-glycine," 
in which carboxyl group of glycine is activated, is 
fed to the reactor (P-6) for the immobilization 
process of thyroglobulin. 
The third stage – covalent interaction between 
the amino groups of thyroglobulin and activated 
carboxyl groups of glycine. This stage lasts for 12-
14 hours. 
The third stage of the process is similar to the 
second, except that the concentrate (buffer particle 
conjugate "PM-glycine," in which the carboxyl 
groups are activated glycine) contained in the reac-
tor (P-6), is fed 0.05% buffer thyroglobulin, taken 
from the tank (E-43), instead of 0.1% of the first 
buffer carbodiimide. 
This method of obtaining diagnostic test system 
"PM-glycine-Tg" provided content of thyroglobulin 
on the surface of 0.4% of the polymer suspension in 
a concentration of 40 µg/mL, and allowed to keep 
the availability of its determinant sites required for 
binding to the active sites of autoantibodies. In the 
resulting concentrate (diagnostic test system "PM-
glycine-Tg"), add a preservative (sodium azide) and 
transfer to the stage of filling, packaging, and label-
ing of diagnostic test system "PM-glycine-Tg". 
Developed diagnostic test system "PM-glycine-
Tg" to detect autoantibodies to thyroglobulin by 
RLA, organoleptic and physical-chemical para-
meters should meet the requirements and standards 
of product quality (test-system) Table 4.  
 
 
Table 4. Valuation parameters as a diagnostic test of the "PM-glycine-Tg"  
to detect autoantibodies to thyroglobulin by RLA 
Indicator Method Display 
Specificity The reaction of latex 
agglutination inhibition 
(RTLA) 
With a positive response RTLA at the bottom 
of microplate well the spot precipitate is formed; at 
the negative agglutinates in the form of the inver-
ted "umbrella" is formed. 
Sensitivity The reaction of latex 
agglutination (RLA) 
Titers reaction RLA 1:10–1:80, 1:80–1:640, 
1:640 and more mean, respectively, the low – 10–
80 IU/mL, average – 80–640 IU/mL, and high – 
640 IU/mL or more content of autoantibodies to 
thyroglobulin. 
Expiration date – 6 months from date of manufacture. In the 
dark place at a temperature between 2 and 8°C. 
 
The diagnostic value of the developed test sys-
tem for detection of autoantibodies to thyroglobulin 
was tested on a panel of healthy human sera (n=30) 
and patients with autoimmune thyroid disease 
(Hashimoto's thyroiditis, Graves') (n=70). 
Serum titers of the samples 1:10–1:80, 1:80–
1:640, 1:640 and > denote, respectively, the low – 
10–80 IU/mL (n = 26), the average – 80–640 
IU/mL (n=23) and high – 640 IU/mL and> (n=16) 
content of autoantibodies to thyroglobulin. 
Comparative analysis of the detection of auto-
antibodies to thyroglobulin methods RLA and the 
traditional method of RIHA (reaction of indirect 
hemagglutunation) showed that the sensitivity of 
the developed diagnostic test systems "PM-glycine-
Tg" to detect autoantibodies to thyroglobulin thy-
roid cancer in human serum is not inferior to the 
method of RIHA, used in clinical practice. Identical 
units of agglutination titers for RLA is 1:10–1:80, 
1:80–1:640,> 1:640 and RIHA – 1:160–1:320, 
1:640–1:1280, 1:10240 – > 1:20480. 
Agreement of the results to identify autoanti-
bodies to thyroglobulin in methods of RLA and 
RIHA observed in 96% of cases. 
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The advantages of the developed diagnostic test 
systems for the RLA, besides stability, shelf life, 
technology, is the fact that the range of the ana-
lyzed serum titers (detection of autoantibodies) 
order of magnitude lower in RLA (1:40–1:640) in 
comparison with RIHA (1:160–1:10240). This ad-
vantage makes it possible to reduce the time of 
posting the analysis 2-3 times. 
By the developed technology have been acqu-
ired 5 series prototype test kits "PM-glycine-Tg", in 
the right quantities. Prototypes of diagnostic test 
systems "PM-glycine-Tg" were presented in sets, 
each of which was designed for the analysis of 12 
donor serum samples (Fig. 3). 
 
Contents of the kit 
1. The plate 96-well polystyrene – 1. 
2. Bottle number 1: Test-system "PM-glycine-
Tg" – 2; 
3. Bottle number 2: Buffer solution (BS) – 2; 
4. Bottle number 3: Negative control serum 
(NC) – 1; 
5. Bottle number 4: Positive control serum (PC) – 1; 
6. Application instruction set – 1. 
 
  
Fig. 3. Contents of set. 
 
Conclusion 
A high-tech technology for highly sensitive test 
systems was proposed based on conjugates "poly-
mer microsphere–bioligand" for express diagnosis 
of autoantibodies to the modified protein (proteo-
pathy) on the example of thyroglobulin, using the 
method of latex agglutination reaction (in vitro). 
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